Ginkgo Biloba Preparations: Toward Discoveries in the Clinical Neuropharmacology

S.H. Burchynskyi

Abstract


The most relevant and current data on the basic mecha­nisms of action of ginkgo biloba extract are presented in the article: neurotransmitter effects, neurometabolic effects, vasotropic effects. Popularity of gingko biloba extract in neurology is related to its efficiency and safety.

Keywords


ginkgo extract, mechanism of action, Bilobil, Bilobil Intens

References


Арушанян Э.Б., Бейер Э.В. Ноотропные свойства препаратов гинкго билоба // Эксп. клин. фармакол. — 2008. — ​Т. 71, № 4. — ​С. 57-63.

Астахова А.В. Побочные эффекты компонентов БАД. Предостережения в отношении их использования в пред- и послеоперационном периодах // Безопасность лекарств. Экспресс-информация. — 2002. — ​С. 16-23.

Бурчинский С.Г. Вазотропная фармакотерапия: новые аспекты // Журн. практ. лікаря. — 2001. — № 6. — ​С. 57-60.

Бурчинский С.Г. Возможности препаратов гинкго в стратегии фармакотерапии сосудистой деменции // Міжнар. неврол. журн. — 2015. — № 6. — ​С. 131-136.

Камчатнов П.Р. Возможности применения экстракта гинкго билоба в неврологической практике // Журн. неврол. психиат. — 2010. — ​Т. 110, № 5. — ​С. 51-56.

Кузнецова С.М., Шульженко Д.В. Экстракт гинкго билоба в стратегии лечения хронических сосудистых заболеваний головного мозга // Міжнар. неврол. журн. — 2015. — № 2. —

С. 109-115.

Мищенко Т.С., Мищенко В.Н., Лапшина И.А. Билобил Интенс в лечении больных с дисциркуляторной энцефалопатией, обусловленной атеросклерозом и артериальной гипертензией // Міжнар. неврол. журн. — 2012. — № 6. — ​С. 9-14.

Старение мозга / Под ред. В.В. Фролькиса. — ​Л.: Наука, 1991. — 277 с.

Штрыголь С.Ю., Кортунова Т.В., Штрыголь Д.В. Побочные эффекты ноотропных средств // Провизор. — 2003. — № 11. — ​http.//www.provisor.com.ua.

Ahlemeyer B., Krieglstein J. Neuroprotective effects of ginkgo biloba extract // Cell. Mol. Life Sci. — 2003. — ​V. 60. — ​P. 1779-1792.

Chan P.C., Xin Q., Fu P.P. Ginkgo biloba leave extract: biological, medicinal and toxicological effects // J. Environ. Sci. Health C. Environ. Carcinog. Ecotoxicol. Rev. — 2007. — ​

V. 25. — ​P. 211-244.

DeFeudis F.V., Drieu K. Ginkgo biloba extract (Egb 761) and CNS functions: basic studies and clinical applications // Curr. Drug Targets. — 2000. — ​V. 1. — ​P. 25-58.

Doody R.S., Stevens J.C., Beck C. et al. Practice parameter: management of dementia (an evidence-based review) // Neuro­logy. — 2001. — ​V. 56. — ​P. 1154-1166.

Eckert A., Koil U., Kressmann S. et al. Effects of EGb 761 Ginkgo biloba extract on mitochondrial function and oxidative stress // Pharmacopsychiatry. — 2003. — ​V. 36, suppl. 1. — ​P. 15-23.

Erdenek P. Vasoactive agents in cerebrovascular pathology // Mag. Clin. Rev. — 2012. — ​V. 11. — ​P. 84-93.

He Y.T., Xing S.S., Gao L. et al. Ginkgo biloba attenuates oxidative DNA damage of human umbilical vein endothelial cells induced by intermittent high glucose // Pharmazie. — 2014. — ​

V. 69. — ​P. 203-207.

Huquet F., Drieu K., Piriou K. Decreased cerebral 5-HT 1a receptors during aging: reversal by Ginkgo biloba extract (Egb 761) // J. Pharm. Pharmacol — ​1994. — ​V. 46. — ​P. 316-318.

Koch E. Inhibition of platelet activating factor (PAF)-induced aggregation of human thrombocytes by ginkgolides: considerations on possible bleeding complications after oral intake of Ginkgo biloba extracts // Phytomedicine. — 2005. — ​V. 12. — ​P. 10-16.

Kristofikova Z., Benesova O., Tejkalova H. Changes of high-affinity choline uptake in the hippocampus of old rats after long-term administration of two nootropic drugs (Tacrine and Ginkgo biloba extract) // Dementia. — 1992. — ​V. 3. — ​P. 304-307.

Li X.X., Chen S.X., Ye G.S. et al. Protective effects of extract of ginkgo biloba on vascular endothelial dysfunction induced by AGEs-BSA in vivo // Zhong Yao Cai. — 2007. — ​V. 30. — ​P. 1109-1113.

Luo Y. Alzheimer’s disease, the nematode Caenorhabditis elegans, and ginkgo biloba leaf extract // Life Sci. — 2006. — ​

V. 78. — ​P. 2066-2072.

Marks I.E. Cure and care of neurosis. — ​N.Y.: J.V. Scott Med. Found., 2001. — 429 p.

Mehta M.A., Riedel W.J. Dopaminergic enhancement of cognitive function // Curr. Pharm. Des. — 2006. — ​V. 12. — ​P. 2487-2500.

Pardon M.C., Joubert C., Perz-Diaz F. et al. In vivo regulation of cerebral monoamine oxidase activity in senescent controls and chronically stressed mice by long-term treatment with Ginkgo biloba extract (EGb 761) // Mech. Ageing Dev. — 2000. — ​

V. 113. — ​P. 157-168.

Rojas P., Ruiz-Sanchez E., Rojas C. et al. Ginkgo biloba extract (Egb 761) modulates the expression of dopamine-related genes in 1-methyl‑4-phenyl‑1,2,3,6-tetrahydropyridine-induced parkinsonism in mice // Neuroscience. — 2012. — ​V. 223. —

P. 246-257.

Sastre J., Lloret A., Borras C. et al. Ginkgo biloba extract EGb 761 protects against mitochondrial aging in the rat brain and in the liver // Cell. Mol. Biol. — 2002. — ​V. 48. — ​P. 685-692.

Schneider L.S., DeKosky S.T., Farlow M.R. et al. A randomized, double-blind, placebo-controlled trial of two doses of ginkgo biloba extract in dementia of the Alzheimer’s type // Curr. Alzheimer’s Res. — 2005. — ​V. 2. — ​P. 541-551.

Shah Z.A., Sharma P., Vohora S.B. Ginkgo biloba normalizes stress-elevated alterations in brain catecholamines, serotonine and plasma corticosterone levels // Eur. Neuropsychopharmacol. — 2003. — ​V. 13. — ​P. 321-325.

Stark M., Behl C. The ginkgo biloba extract Egb 761 modulates proteasome activity and polyglutamine protein aggregation // Evidence-Based Complement. Alternat. Med. — 2014. — ​ID940186. — 14 p.

Stoll S., Scheuer K., Pohl O. et al. Ginkgo biloba extract (EGb 761) independently improves changes in passive avoidance learning and brain membrane fluidity in the aging mouse // Pharmacopsychiatry. — 1996. — ​V. 29. — ​P. 144-149.

Sun B., Hu Y., Yuan H. et al. Extract of Ginkgo biloba promotes the expression of VEGF followed subarachnoid hemorrhage in rats // Int. J. Neurosci. — 2009. — ​V. 119. — ​P. 995-1005.

Terry A.V., Buccafusco J.J. The cholinergic hypothesis of age- and Alzheimer’s disease-related cognitive deficit: recent challenges and their implications for novel drug development // J. Pharmacol. Exp. Ther. — 2003. — ​V. 306. — ​P. 821-827.

Wan W., Cao L., Liu L. et al. Egb 761 provides a protective effect against Abeta1-42 oligomer-induced cell damage and blood-brain barrier disruption in an in vitro bEnd.3 endothelial model // Plos One. — 2014. — ​ID0113126.

Watanabe C.M.H., Wolffram S., Ader P. et al. The in vivo neuromodulatory effects of the herbal medicine ginkgo biloba // PNAS. — 2001. — ​V. 98. — ​P. 6577-6580.

Yoshitake T., Yoshitake S., Kehr J. The ginkgo biloba extract Egb 761 and its main constituent flavonoids and ginkgolides increase extracellular dopamine levels in the rat prefrontal cortex //

Brit. J. Pharmacol. — 2010. — ​V. 159. — ​P. 659-668.




DOI: https://doi.org/10.22141/2224-0713.4.90.2017.107261

Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 INTERNATIONAL NEUROLOGICAL JOURNAL

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru